Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone Combined With Dalpiciclib in HER-2-Negative, AR-Positive Recurrent/Metastatic Salivary Gland Carcinoma
NCT07815522Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abiraterone and dalpiciclib in salivary gland carcinoma (SGC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective Response Rate at 12 months. Started Oct 2026; status: recruiting.
02
Drugs
abirateronedalpiciclib
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT07815522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815522.